

CURRICULUM VITAE

Name Konstantinos P. Makaritsis, M.D., Ph.D
Date of birth March 22, 1961
Place of birth Athens, Greece
Marital status Married, two children
Languages spoken English, Greek



Larissa, February 24, 2013

Contact:

Konstantinos P. Makaritsis, M.D., Ph.D
Assistant Professor of Medicine
University Hospital of Larissa, Department of Internal Medicine
Mezourlo, 41110, Larissa, Greece
Tel. +30-2413501558, Fax. +30-2413501557
Cell Phone: +30-6932460923
email: makarits@med.uth.gr

POSITION TITLE: Assistant Professor of Medicine, Department of Medicine, University of Thessaly School of Medicine, Larissa, Greece

<u>INSTITUTION AND LOCATION</u>	<u>DEGREE</u>	<u>YEAR CONFERRED</u>	<u>FIELD OF STUDY</u>
University of Patras School of Medicine, Patras, Greece.	M.D.	1985	Medicine
University of Athens School of Medicine, Athens, Greece.	Ph.D	1995	Cardiovascular Medicine
Greek Ministry of Health, Greece	IM Boards	1995	Internal Medicine
USMLE, Philadelphia, USA	USMLE 1,2	1995	ECFMG Certificate
ATLS, Hellenic National Center Patras, Greece	ATLS Course	2005	
ATLS, Hellenic National Center Patras, Greece	ATLS Instructor	2007	
(Advanced Trauma Life Support, American College of Surgeons)			

Membership in Professional Societies

1995 - Hellenic Society for the Study of Stroke
1997 - Massachusetts Medical Society
1998 - American Association for the Advancement of Science
1998 - New York Academy of Sciences
1998 - American Heart Association

2008 - Hellenic Society for the Study of Hypertension

2008 - Hellenic Society of Internal Medicine of Northern Greece

Doctorate (Thesis):

"Comparison of the hemodynamic effects of the paraaortic counterpulsation device to those of a centrifugal blood pump (left atrium-aorta) in acute heart failure. An experimental study." University of Athens School of Medicine, Athens, Greece, 1995.

Professional (Clinical) experience

1. 1985-1987: Physician of the Greek Navy (military service). Certificate in Diving Medicine (February 21, 1986).
2. 1987-1988: Community physician at Avramio, Messinia, Greece.
3. 1988-1989: Physician of the Greek Social Insurance Foundation, Piraeus, Greece.
4. 1989-1990: Physician of the Elefsina Health Center, Elefsina, Greece.
5. 1990-1995: Residency in Internal Medicine, Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece (1994-95 as Chief Resident).
6. 1995-1996: Attending Physician, Internal Medicine, "Hygeia" Diagnostic and Therapeutic Center of Athens, Athens, Greece.
7. 1997-1999: Clinical & Research Fellow, Boston University Medical Center, Department of Medicine, Section of Hypertension and Atherosclerosis, Boston, MA, USA.
8. 2000-2004: Director, Department of Internal Medicine, Mediterraneo Hospital, Athens, Greece
9. 2005-present:
 - Assistant Professor of Medicine, Department of Medicine, University of Thessaly School of Medicine, Larissa, Greece.
 - Attending Physician, Department of Medicine, University of Thessaly School of Medicine, Larissa University Hospital, Larissa, Greece.
 - Chief, Hypertension Outpatient Clinic, Department of Medicine, University of Thessaly School of Medicine, Larissa University Hospital, Larissa, Greece.

Research experience

1. 1991-1995: Conducted research in the use of heart assist devices (intraaortic balloon pump, paraaortic balloon pump, centrifugal blood pump) in experimental heart failure and cardiogenic shock in dogs. (P.I.: J.N. Nanas, MD and S.D. Mouloupoulos, MD. Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece).
2. 1991-1994: Actively participated in clinical follow-up of heart transplant recipients. (P.I.: J.N. Nanas, MD and S.D. Mouloupoulos, MD. Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece).

3. 1992-1995: Actively participated in clinical study, evaluating outcome, morbidity and mortality with various treatment regimens in patients with congestive heart failure. (P.I.: J.N. Nanas, MD and S.D. Mouloupoulos, MD. Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece).
4. 1992-1993: Participated in a prospective epidemiologic study, evaluating the influence of various risk factors for coronary heart disease in Greek population. (P.I.: S.N. Nanas, MD and S.D. Mouloupoulos, MD. Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece).
5. 1994-1995: Actively participated in clinical research, evaluating infections and clinical outcome in patients with acute stroke, admitted in stroke unit. (P.I.: K. Vemmos, MD, K. Georgilis, MD and S.D. Mouloupoulos, MD. Department of Clinical Therapeutics, University of Athens School of Medicine, "Alexandra" Hospital, Athens, Greece).
6. 1997-1999: (Boston University Medical Center, Department of Medicine, Section of Hypertension and Atherosclerosis, Boston, MA, USA.)

A. Conducted research to determine the role of α_2 adrenergic receptors in blood pressure regulation and hypertension in mice. The goals of the studies were to define the contribution of each of the three α_2 adrenergic receptor subtypes (α_{2A} , α_{2B} , α_{2C}) in controlling blood pressure, regulating hormone and catecholamine release, regulating renal sodium and water excretion and vasoconstriction, using knockout mice lacking one of the three α_2 adrenergic receptor subtype gene. DOCA-salt, subtotal nephrectomy plus salt loading, and renovascular hypertension are the models used for development of experimental hypertension in knockout and wild-type mice. Acute salt infusion was performed in normal and kidney deprived mice to determine the effect of sodium load on blood pressure, renal sodium and water excretion and the release of catecholamines and vasopressin. Catheterization of the iliac artery and vein were used to obtain direct blood pressure measurements, salt infusion and collect blood for plasma catecholamine levels determination. (P.I.: H. Gavras, MD. Hypertension and Atherosclerosis Section, Department of Medicine, Boston University Medical Center, Boston, MA, USA).

B. Conducted research to define the role of hypertension as a risk factor for atherosclerosis. We used the apolipoprotein E-deficient mouse as a model for atherosclerosis to determine if antihypertensive drug treatment regimens influence vascular changes in this hyperlipidemic animal model. Systolic blood pressure and heart rate measurements were obtained throughout the treatment period. At the end of the treatment period aortic atherosclerosis and plasma lipid levels were measured. The relationship between blood pressure changes and inhibition in the progression of atherosclerosis by drug treatment, provided useful information in defining the mechanisms underlying the development of atherosclerotic lesions in this animal model. (P.I.: P. Brecher, PhD. Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA).

C. Conducted research to determine the role of A3 adenosine receptor in blood pressure regulation and hypertension in mice. (P.I.: Katya Ravid, D.Sc., Ph.D. Associate Professor of

Biochemistry Department of Biochemistry, Boston University School of Medicine & H. Gavras, MD. Hypertension and Atherosclerosis Section, Department of Medicine, Boston University Medical Center, Boston, MA, USA).

7. 2000-2005: Actively participated in a clinical study, prospectively evaluating cardiac function, outcome, morbidity and mortality in cancer patients treated with cardiotoxic chemotherapy. (P.I: L. Kaklamanis, MD, Ph.D, Director of Pathology, Onassis Cardiac Surgery Center, 2nd Department of Cardiology, Athens, Greece.
8. 2005-present:
 - Contributing as P.I. in clinical study evaluating the prevalence of hypertensive patients under treatment achieving blood pressure control in Greece. The ARTEMIS Registry.
 - Actively participated in the Hellenic multicenter clinical study, prospectively evaluating the combination of irbesartan plus hydrochlorothiazide in Greek hypertensive patients. The ZEUS study.
 - Participated in the International multicenter clinical study, prospectively evaluating the benefit of rivaroxaban in preventing stroke and peripheral embolism in patients with atrial fibrillation. The ROCKET study.
 - Actively participated in the Hellenic multicenter clinical study collecting data in stroke patients. Hellas Stroke Registry.
 - Conducting research in ApoE knockout mice (78 mice), evaluating the influence of various immunomodulatory substances in the atherosclerosis area of the aorta.
 - Participating in the National multicenter clinical study, prospectively evaluating the benefit of antibiotic treatment in secondary prevention and outcome of stroke. The ARISTEIDIS study.
 - Participating in the International multicenter clinical study, prospectively evaluating the benefit of nitroglycerin in secondary prevention and outcome of stroke. The ENOS study.

Publications

1. Nanas JN, Nanas SN, Kontoyannis DA, Moussoutzani KS, Hatzigeorgiou JP, Heras PB, **Makaritsis KP**, Agapitos EB, Mouloupoulos SD. Myocardial salvage by the use of reperfusion and intraaortic balloon pump: experimental study. *Ann. Thorac. Surg.* 1996; 61: 629-634.
IF: 2.022

2. Nanas SN, Nanas JN, Charitos CE, Gougoulakis A, **Makaritsis K**, Chatzigeorgiou J, Moussoutzani K, Anastasiou-Nana MI, Mouloupoulos SD. High stroke volume para-aortic counterpulsation device versus centrifugal pump in cardiogenic shock: experimental study. *World J. Surg.* 1997; 21: 318-322. **IF: 1.778**
3. **Makaritsis KP**, Gavras H, Du Y, Chobanian AV, Brecher P. Alpha 1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. *Hypertension.* 1998; 32: 1044-1048. **IF: 7.194**
4. **Makaritsis KP**, Handy DE, Johns C, Kobilka B, Gavras I, Gavras H. Role of the α_{2B} -adrenergic receptor in the development of salt-induced hypertension. *Hypertension.* 1999; 33: 14-17. **IF: 7.194**
5. **Makaritsis KP**, Johns C, Gavras I, Altman JD, Handy DE, Bresnahan MR, Gavras H. Sympathoinhibitory function of the α_{2A} -adrenergic receptor subtype. *Hypertension.* 1999; 34: 403-407. **IF: 7.194**
6. **Makaritsis KP**, Johns C, Gavras I, Gavras H. Role of alpha(2)-adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. *Hypertension.* 2000; 35:609-613. **IF: 7.194**
7. Zhao Z*, **Makaritsis K***, Francis CE, Gavras H, Ravid K. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. *Biochim. Biophys. Acta* 2000; 1500(3):280-290.*(Equal contribution) **IF: 2.371**
8. Sugiyama F, Churchill GA, Higgins DC, Johns C, **Makaritsis KP**, Gavras H, Paigen B. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. *Genomics* 2001; 71(1): 70-77. **IF: 3.613**
9. **Makaritsis KP**, Liakopoulos V, Leivaditis K, Eleftheriadis T, Stefanidis I. Adaptation of renal function in heart failure - Review. *Renal Failure* 2006; 28(7): 527-535. **IF: 0.623**
10. Dalekos GN, **Makaritsis K**, Rigopoulou EI. Redesigning training for internal medicine. *Ann Intern Med* 2006; 145(11): 865. **IF: 15.516**
11. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, **Makaritsis K**, Adamopoulos S, Revela I, Athanasiou A, Mavroudis D, Georgoulas V. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. *Int J Cardiol.* 2007;122(3):195-201. **IF: 2.878**
12. Tsourous GI, Raftopoulos LG, Kafe EE, Manoleris EK, **Makaritsis KP**, Pinis SG. A case of pseudomembranous colitis presenting with massive ascites. *Eur J Intern Med.* 2007;18(4):328-330. **IF: 1.385**

13. Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, **Makaritsis K**, Germenis A, Dalekos GN. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. *Am J Gastroenterol*. 2008;103(3):605-614. **IF: 6.101**
14. Davas EM, Alexiou I, Boulbou M, Koutroumpas A, **Makaritsis K**, Stathakis N, Sakkas LI. Comorbidities increase the risk of serious infections in patients with rheumatoid arthritis treated with TNFalpha inhibitors. *J Infect*. 2008;57(5):418-420. **IF: 2.844**
15. **Makaritsis KP**, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. *Int J Infect Dis*. 2009;13(4):e157-60 **IF: 2.250**
16. Kapsalaki E, Gatselis N, Stefos A, **Makaritsis K**, Vassiou A, Fezoulidis I, Dalekos GN. Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. *Int J Infect Dis*. 2009;13(5):564-9. **IF: 2.250**
17. Sakkas LI, Davas EM, Kapsalaki E, Boulbou M, **Makaritsis K**, Alexiou I, Tsikrikas T, Stathakis N. Hematogenous spinal infection in central Greece. *Spine* (Phila Pa 1976). 2009;34(15):E513-8. **IF: 2.624**
18. **Makaritsis KP**, Neocleous C, Gatselis N, Petinaki E, Dalekos GN. An immunocompetent patient presenting with severe septic arthritis due to *Ralstonia pickettii* identified by molecular-based assays: a case report. *Cases J*. 2009;2:8125.
19. Gatselis NK, **Makaritsis KP**, Gabranis I, Stefos A, Karanikas K, Dalekos GN. Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. *J Med Case Reports*. 2011;5(1):22.
20. Gatselis NK, Liamis G, **Makaritsis KP**, Dalekos GN. Metabolic acidosis during treatment of mushroom poisoning: a diagnostic pitfall. *Intern Med*. 2012;51(9):1077-80.
21. Ntaios G, Vemmou A, Koroboki E, Savvari P, **Makaritsis K**, Saliaris M, Andrikopoulos G, Vemmos K. The type of atrial fibrillation is associated with long-term outcome in patients with acute ischemic stroke. *Int J Cardiol*. 2012 May 16. [Epub ahead of print]
22. Giannikopoulos G, Antonopoulou A, Kalpakou G, **Makaritsis K**, Panou C, Papadomichelakis E, Sinapidis D, Theodotou A, Tzagkaraki A, Giamarellos-Bourboulis EJ. The functional role of natural killer cells early in clinical sepsis. *APMIS*. 2012 Oct 17. doi: 10.1111/apm.12002. [Epub ahead of print]
23. Ntaios G, Papavasileiou V, Diener HC, **Makaritsis K**, Michel P. Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient

- Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Stroke*. 2012 Nov 13. [Epub ahead of print]
24. Gatselis NK, Ntaios G, **Makaritsis K**, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. *Clin Exp Med*. 2013 Jan 5. [Epub ahead of print] PMID: 23292294.
25. Ntaios G, Gatselis NK, **Makaritsis K**, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. *Atherosclerosis*. 2013 Jan 8. [Epub ahead of print] PMID: 23332774.
26. Ntaios G, Lip G, **Makaritsis K**, Papavasileiou V, Vemou A, Koroboki E, Savvari P, Manios E, Milionis H, Vemmos K. CHADS₂, CHA₂DS₂-VASc and long-term stroke outcome in patients without atrial fibrillation. *Neurology*/2013/Feb 13. [Epub ahead of print] PMID:23408865.

Citations

Total Citations: 463

Author *h index* = 8

Referees

1. Spyridon D. Mouloupoulos, M.D.
Professor of Medicine
Department of Clinical Therapeutics
University of Athens School of Medicine
"Alexandra" Hospital, 80, Vas. Sofias - K. Lourou Street
Athens 11528, Greece. Tel. 210- 779-1694, FAX 210-777-0473
2. Haralambos P. Gavras, M.D.
Professor of Medicine
Chief, Hypertension and Atherosclerosis Section
Department of Medicine
Boston University School of Medicine
715 Albany Str. W508, Boston, MA 02118-2526, U.S.A.
Tel. 617-638-4025, FAX 617-638-4027
email: hgavras@bu.edu
3. George N. Dalekos, M.D., Ph.D.
Professor of Medicine
Director, Department of Medicine & Research Lab of Internal Medicine
University of Thessaly School of Medicine
Larissa University Hospital, Biopolis, 41110, Larissa, Greece
Tel. +30-2413502798, Fax. +30-2413501557
email: dalekos@med.uth.gr